2005 AES annual course: Evidence used to treat women with epilepsy

Epilepsia

Volumn 47, Issue SUPPL. 1, 2006, Pages 46-53

  Pennell, Page B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drugs; Breastmilk; Epilepsy; Hormones; Malformations; Menopause; Pregnancy; Women

Indexed keywords

CARBAMAZEPINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ETHOSUXIMIDE; FOLIC ACID; LAMOTRIGINE; MEDROXYPROGESTERONE ACETATE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROGESTERONE; SEX HORMONE; VALPROIC ACID;

BREAST MILK; CATAMENIAL EPILEPSY; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; DEVELOPMENTAL DISORDER; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; EPILEPSY; EVIDENCE BASED MEDICINE; GLUCURONIDATION; HORMONE SUBSTITUTION; HUMAN; LACTATION; MENOPAUSE; MONOTHERAPY; MULTIPLE MALFORMATION SYNDROME; OBSERVATIONAL STUDY; OPEN STUDY; POSTMENOPAUSE; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SPINA BIFIDA; SUPPLEMENTATION; UROGENITAL TRACT DISEASE; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; BREAST FEEDING; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; POSTMENOPAUSE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SEX FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 33749518296     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00660.x     Document Type: Review

References (47)

1. Herzog AG, Klein P, Ransil B. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-8.
2. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004;56:431-4.
3. Smith SS, Woolley CS. Cellular and molecular effects of steroid hormones on CNS excitability. Cleve Clin J Med 2004;71(suppl. 2):S4-10.
4. Herzog A. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995;45:1660-2.
5. Herzog A. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999;52:1917-8.
6. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397-428.
7. Harden CL, Pulver MC, Ravdin L, et al. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999;40:1402-7.
8. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; in press.
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
10. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology 1998;51:944-8.
11. Honein MA, Paulozzi LJ, Mathews TJ, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285:2981-6.
12. MRC Vitamin Study Research Group. Prevention of neural-tube defects: results of the Medical Researdh Council Vitamin Study. Lancet 1991;338:131-7.
13. Hernandez-Diaz S, Werler M, Walker A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14.
14. Nambisan M, Wyszynski DF, Holmes LB. No evidence of a protective effect due to periconceptional folic acid (PCFA) intake on risk for congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (AEDs). Birth Defects Res 2003;67:5.
15. Vajda FJ, O'Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003;10:543-9.
16. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. Br Med J 2000;321:674-5.
17. Holmes LB. The teratogenecity of anticonvulsant drugs: a progress report. J Med Genet 2002;39:245-7.
18. Pennell PB. The importance of monotherapy in pregnancy. Neurology 2003;60:S31-8.
19. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004;45:1463-4.
20. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004;61:673-8.
21. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-5.
22. Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia 2004;45:1465.
23. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8.
24. Isojarvi JI, Cunnington M, Messenheimer JA. Twelve years of monitoring through an inernational observational study of pregnancy outcomes folowing exposure to lamotrigine (abstract). Epilepsia 2005;46(suppl. 6): 110.
25. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67:407-12.
26. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004;11:854-8.
27. Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005;112:137-43.
28. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Australian pregnancy registry of women on antiepileptic drugs: 5 year results (abstract). Epilepsia 2004; 45(suppl. 7): 234.
29. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61:S35-42.
30. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62:292-5.
31. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005;65:185-8.
32. Pennell P, Montgomery J, Clements S, et al. Lamotrigine clearance markedly increases during pregnancy. Epilepsia 2002;43:234.
33. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-3.
34. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-1.
35. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005;46:1414-7.
36. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006;66:354-60.
37. Meador KJ, Zupanc ML. Neurodevelopmental outcomes of children born to mothers with epilepsy. Cleve Clin J Med 2004;71(suppl. 2):S38-41.
38. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
39. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32.
40. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83.
41. Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64:949-54.
42. Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000;343:118-26.
43. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89.
44. Morrell M. Guidelines for the care of women with epilepsy. Neurology 1998;51:S21-7.
45. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonata and during lactation. Epilepsia 2000;41:709-13.
46. Pennell PB, Ritchie JC, Newport DJ, et al. Pharmacokinetics of lamotrigine excretion into human breast milk (abstract). Neurology. 2006; 66(suppl. 2): A72-3.
47. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005;46:775-7.